Clinical trials: Coinfection, HIV
HIV/AIDS
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
The primary objective of the proposed phase I trial is to evaluate the safety and tolerability of DNA-HIV-PT123 and AIDSVAX®B/E combination regimen.
- Trial name
- EV06 (NCT02376582)
- Testing
- DNA, AIDSVAX B/E
- Where
- 2 sites in Uganda
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- EuroVacc Foundation
Hepatitis B, HIV Infections
Hepatitis B and HIV Co-Infection in Patients in Uganda
This study will determine the amount of liver scarring (fibrosis) or liver damage in people infected with 1) hepatitis B virus (HBV, a virus that can infect the liver); 2) HIV (the virus that causes AIDS); 3) both HBV and HIV…
- Trial name
- NCT00782158
- Where
- 2 sites in Uganda
- Volunteers
- 6,303 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Pulmonary, HIV/AIDS
RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection
Although tuberculosis is a treatable disease, it is currently the infectious disease with the highest mortality in the world. It is estimated that one-third of the world's population is infected.
- Trial name
- RIPENACTB (NCT03281226)
- Testing
- RIPE (2m) and RI (4m), RIPE+NAC (2m) and RI (4m)
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Hepatitis C, HIV Infections
Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV
The purpose of this study is to measure the effects of anti-HIV drugs on hepatitis C virus (HCV) viral load in people infected with both HCV and HIV.
- Trial name
- ART and HCV (NCT00545558)
- Testing
- Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Cincinnati
Infection, Human Immunodeficiency Virus, HIV Infections
Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection
HIV/Tuberculosis (TB) co-infection have profound effects on the host's immune system. TB is the most common cause of death in patients with HIV worldwide.
- Trial name
- NCT02178592
- Testing
- DTG 50 mg, EFV 600 mg
- Where
- 28 sites in Argentina, Brazil and 5 more
- Volunteers
- 113 people
- Sponsor
- ViiV Healthcare
Drug-resistant Tuberculosis, HIV Coinfection
Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.
- Conditions
- Drug-resistant Tuberculosis, HIV Coinfection, Cost-Benefit Analysis
- Trial name
- TSELiOT (NCT05553236)
- Testing
- Targeted next-generation sequencing
- Where
- South Africa
- Volunteers
- 2,500 people
- Sponsor
- University of California, San Francisco
Hiv, Visceral Leishmaniasis
Recurrent Visceral Leishmaniasis in HIV Co-Infection
The aim is (1) to better understand the underlying causes and predispositions for relapse and parasite persistence in visceral leishmaniasis (VL) patients living with HIV and (2) to improve treatment monitoring of this target…
- Trial name
- ALIVE (NCT07487350)
- Where
- Ethiopia
- Volunteers
- 20 people
- Sponsor
- Institute of Tropical Medicine, Belgium
HIV Infections, Hepatitis C
Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection
To show the feasibility of liver transplantation in HCV-HIV coinfected patients. To study the two-year survival after transplantation, the interaction between HCV and HIV after transplantation, the influence of HIV on HCV…
- Trial name
- NCT00158535
- Testing
- liver transplantation
- Where
- France
- Volunteers
- 15 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis D Virus Infection
HDV Screening Study
This is a territory-wide cross-sectional study of all individuals living with HIV/HBV coinfection and HBV-related HCC.
- Trial name
- NCT06889805
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- Grace Lai Hung Wong
Hepatitis C, HIV
HCV Treatment in HIV Co-Infected Patients in Asia
The purpose of this study is to assess the effectiveness and tolerability of hepatitis C virus (HCV) treatment in HIV co-infected patients in routine health care services in Asia through a pilot model of care for treatment of HCV…
- Trial name
- NCT01838772
- Testing
- Pegylated-Interferon and Ribavirin
- Where
- 4 sites in Indonesia, Malaysia and 2 more
- Volunteers
- 188 people
- Sponsor
- amfAR, The Foundation for AIDS Research
Hepatitis, Hepatitis C
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic hepatitis C in Human Immunodeficiency Virus-1…
- Conditions
- Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection
- Trial name
- NCT02103439
- Testing
- Algeron, PegIntron
- Where
- 6 sites in Russia
- Volunteers
- 140 people
- Sponsor
- Biocad
Hepatitis C Infection, HIV Infection
A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures
Background: Chronic hepatitis C (CHC) is a major health problem that particularly affects individuals with human immunodeficiency virus (HIV) infection, and can lead to cirrhosis and liver failure.
- Trial name
- NCT01185028
- Testing
- Nitazoxanide With Pegylated Interferon And Ribavirin
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV
Epidemiological Study of HIV in the South African National Defense Force
This project, called PHIDISA I, will screen uniformed personnel of the South African National Defense Force (SANDF) and their registered family members for HIV, hepatitis B and C, gonorrhea, syphilis, and chlamydia to determine…
- Trial name
- NCT00341887
- Where
- 5 sites in South Africa
- Volunteers
- 8,676 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, HIV Infections
Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP)
Hepatitis C and HIV infect worldwide millions of people leading to a high rate of coinfected patient with eventually liver cirrhosis and endstage liver disease.
- Trial name
- NCT00150904
- Testing
- venous blood puncture
- Where
- Netherlands
- Volunteers
- 28 people
- Sponsor
- UMC Utrecht
Hepatitis C
Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
The aim of the study is to determine if treatment for recently acquired hepatitis C infection (with or without HIV coinfection) can be shortened when treating with the interferon-free therapy sofosbuvir/velpatasvir (SOF/VEL).
- Trial name
- REACT (NCT02625909)
- Testing
- SOF/VEL for 6 weeks, SOF/VEL for 12 weeks
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 222 people
- Sponsor
- Kirby Institute
Acquired Immunodeficiency Syndrome, Tuberculosis
Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB
The purpose of this study is to determine the lopinavir levels in blood of HIV and TB infected children (3-15kg) when given lopinavir/ritonavir in a 1:1 ratio with rifampicin containing TB regimen and its safety.
- Trial name
- NCT02348177
- Testing
- lopinavir with ritonavir in 1:1 ratio, Lopinavir/ritonavir 4:1
- Where
- 5 sites in South Africa
- Volunteers
- 96 people
- Sponsor
- Drugs for Neglected Diseases
HIV/HCV Coinfection
Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)
This is an uncontrolled, open-label, Phase III trial of peginterferon alfa-2a (Pegasys) in participants coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV).
- Trial name
- NCT02762383
- Testing
- Peginterferon Alfa-2
- Where
- 10 sites in Belgium
- Volunteers
- 19 people
- Sponsor
- Hoffmann-La Roche
Depression, HIV Infections
Trial of Citalopram for the Prevention of Depression
With the improved prognosis of human immunodeficiency virus (HIV) infection, end stage liver disease due to hepatitis C (HCV) now represents a major cause of morbidity and mortality in people with HIV.
- Conditions
- Depression, HIV Infections, Hepatitis C
- Trial name
- PICCO (NCT00317746)
- Testing
- Citalopram
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- Marina Klein
HIV, Hepatitis C
Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection
End-stage liver disease, predominantly due to hepatitis C virus (HCV) infection, is one of the leading causes of death in person living with HIV infection.
- Conditions
- HIV, Hepatitis C, Co-Infection
- Trial name
- NCT02294136
- Testing
- Prep-C, Educational Control
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatitis C, Chronic, HIV
Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C
Response-guided triple-therapy with boceprevir (BOC) in combination with pegylated interferon (PEGIFN) and ribavirin (RBV) is the current standard of care for HIV-negative patients infected with hepatitis C genotype (HCV-GT) 1.
- Trial name
- HIVCOBOC-RGT (NCT01925183)
- Testing
- Pegylated interferon alpha-2a, Ribavirin, Boceprevir
- Where
- Austria
- Volunteers
- 6 people
- Sponsor
- Markus Peck-Radosavljevic